Bioline Rx Ltd ADR [NASDAQ: BLRX] plunged by -$0.02 during the normal trading session on while it closed the day at $0.10.
Bioline Rx Ltd ADR stock has also loss -28.97% of its value over the past 7 days. However, BLRX stock has declined by -78.40% in the 3 months of the year. Over the past six months meanwhile, it has lost -87.15% and lost -52.57% year-on date.
The market cap for BLRX stock reached $14.45 million, with 142.34 million shares outstanding and 141.55 million shares in the current float. Compared to the average trading volume of 6.50M shares, BLRX reached a trading volume of 25716824 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Bioline Rx Ltd ADR [BLRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BLRX shares is $4.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BLRX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Bioline Rx Ltd ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 18, 2017. While these analysts kept the previous recommendation, Rodman & Renshaw raised their target price to Buy. The new note on the price target was released on February 13, 2017, representing the official price target for Bioline Rx Ltd ADR stock. Previously, the target price had yet another drop from $4 to $1, while Maxim Group kept a Hold rating on BLRX stock. On August 17, 2015, analysts decreased their price target for BLRX shares from 8 to 4.
The Average True Range (ATR) for Bioline Rx Ltd ADR is set at 0.04, with the Price to Sales ratio for BLRX stock in the period of the last 12 months amounting to 0.66. The Price to Book ratio for the last quarter was 0.95, with the Price to Cash per share for the same quarter was set at 0.20.
BLRX stock trade performance evaluation
Bioline Rx Ltd ADR [BLRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -28.97. With this latest performance, BLRX shares dropped by -52.57% in over the last four-week period, additionally sinking by -87.15% over the last 6 months – not to mention a drop of -92.59% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BLRX stock in for the last two-week period is set at 28.66, with the RSI for the last a single of trading hit 27.02, and the three-weeks RSI is set at 30.01 for Bioline Rx Ltd ADR [BLRX]. The present Moving Average for the last 50 days of trading for this stock 0.2785, while it was recorded at 0.1177 for the last single week of trading, and 0.5494 for the last 200 days.
Bioline Rx Ltd ADR [BLRX]: An insightful look at the core fundamentals
Bioline Rx Ltd ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.37 and a Current Ratio set at 1.52.
Bioline Rx Ltd ADR [BLRX]: Institutional Ownership
The top three institutional holders of BLRX stocks are: ALYESKA INVESTMENT GROUP, L.P. with ownership of 1.95 million shares, which is approximately 2.6966%. CVI HOLDINGS, LLC, holding 0.82 million shares of the stock with an approximate value of $$0.46 million in BLRX stocks shares; and CVI HOLDINGS, LLC, currently with $$0.12 million in BLRX stock with ownership which is approximately 0.2952%.
